Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 4
Submit an article Journal homepage
105
Views
5
CrossRef citations to date
0
Altmetric
Review

Adjunctive strategies in the treatment of refractory bipolar depression: clinician options in the absence of a systematic database

Robert M Post National Institute of Mental Health, Biological Psychiatry Branch, National Institutes of Health, Department of Health and Human Services, 10 Center Drive MSC 1272, Bldg. 10, Room 3S239, Bethesda MD 20892-1272, USA. [email protected]
Pages 531-546 | Published online: 22 Apr 2005

Bibliography

  • JUDD LL, AKISKAL HS, SCHETTLER PJ et al.: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry (2002) 59:530–537.
  • ••Weeks depressed exceed weeks manic by afactor of three.
  • POST RM, DENICOFF KD, LEVERICH GS et al.: Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH Life Chart Method. J. Clin. Psychiatry (2003) 64:680–690.
  • ••Days depressed exceed days manic by afactor of three, despite intensive psychopharmacological treatment.
  • NOLEN WA, LUCKENBAUGH DA, ALTSHULER LL et al.: Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network. Am. J. Psychiatry (2004) 161:1447–1454.
  • ••Prior severity of depression, mania, andcycling has some predictive value in assessing these outcomes prospectively.
  • POST RM: Preface and Overview. Clin. Neurosci. Res. (2002) 2:122–126.
  • •An overview of the deficits in the bipolar depression research portfolio.
  • LEVERICH GS, POST RM: Life charting the course of bipolar disorder. Current review of mood and anxiety disorders (1996) 1:48–61.
  • LEVERICH GS, POST RM: Life chartingof affective disorders. CNS Spectrums (1998) 3:21–37.
  • POST RM, LUCKENBAUGH DA: Unique design issues in clinical trials of patients with bipolar affective disorder. J. Psychiatr. Res. (2003) 37:61–73.
  • •Many aspects of the traditional RCT are ill-suited and poorly matched to the diversity and heterogeneity of presentation of bipolar disorder.
  • DUFFY A, ALDA M, KUTCHER S et al: A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. J. Clin. Psychiatry (2002) 63:1171–1178.
  • •Family history of lithium response to some extent breeds true.
  • CALABRESE JR, MARKOVITZ PJ, KIMMEL SE, WAGNER SC: Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J. Clin. Psychopharmacol (1992) 12:53S–56S.
  • CALABRESE JR, WOYSHVILLE MJ, KIMMEL SE, RAPPORT DJ: Predictors of valproate response in bipolar rapid cycling. Clin. Psychopharmacol. (1993) 13:280–283.
  • CALABRESE JR, FATEMI SH, KUJAWA M, WOYSHVILLE MJ: Predictors of response to mood stabilisers. Clin. Psychopharmacol. (1996) 16:24S–31S.
  • GREIL W, KLEINDIENST N, ERAZO N, MULLER-OERLINGHAUSEN B: Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J. Clin. Psychopharmacol (1998) 18:455–460.
  • •Clinical correlates of response to these two agents differ remarkably.
  • GROF P: Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. J. Clin. Psychiatry (2003) 64\(Suppl. 5):53–61.
  • PASSMORE MJ, GARNHAM J, DUFFY A et al.: Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord. (2003) 5:110–114.
  • ••Unexpected correlates of lamotrigineresponse in the area of personal and positive family history of anxiety disorders were found.
  • POST RM, SPEER AIVI, OBROCEA GV,LEVERICH GS: Acute and prophylactic effects of anticonvulsants in bipolar depression. Clin. Neurosci. Res. (2002) 2:228–251.
  • •Heterogeneity of drug action and clinical effectiveness in bipolar disorder is reviewed.
  • POST RM, UHDE TW, ROY-BYRNE PP, JOFFE RT: Antidepressant effects of carbamazepine. Am. J. Psychiatry (1986) 143:29–34.
  • POST RM, UHDE TW, ROY-BYRNE PP, JOFFE RT: Correlates of antimanic response to carbamazepine. Psychiatry Res. (1987) 21:71–83.
  • POST RM, SPEER AM, LEVERICH GS:Complex combination therapy: the evolution toward rational polypharmacy in lithium-resistant bipolar illness. In: 50 Years: The Psychopharmacology of Bipolar Ilness. Akiskal H, Tohen M (Eds.), John Wiley & Sons Ltd., London (2005) In press.
  • •Polytherapy is the current clinical norm and is often a necessity in the treatment of bipolar illness.
  • GHAEMI SN, ROSENQUIST KJ, KO JY et al.: Antidepressant treatment in bipolar versus unipolar depression. Am. J. Psychiatry (2004) 161:163–165.
  • THASE ME, SACHS GS: The challenges of pharmacotherapy of bipolar depression. Clin. Neurosci. Res (2002) 2:213–221.
  • YOUNG LT, JOFFE RT, ROBB JC et al.:Double-blind comparison of addition of a second mood stabiliser versus an antidepressant to an initial mood stabiliser for treatment of patients with bipolar depression. Am. J. Psychiatry (2000) 157:124–126.
  • KUPKA RW, LUCKENBAUGH DA, POST RM, LEVERICH GS, NOLEN WA: Rapid and non-rapid cycling in bipolar disorder: a meta-analysis of clinical studies. J. Clin. Psychiatry (2003) 64:1483–1494.
  • SCHNECK CD, MIKLOWITZ DJ, CALABRESE JR et al.: Phenomenology of rapid-cycling bipolar disorder: data from the first 500 participants in the systematic treatment enhancement program. Am. J. Psychiatry (2004) 161:1902–1908.
  • GIJSMAN HJ, GEDDES JR, RENDELL JM, NOLEN WA, GOODWIN GM: Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am. J. Psychiatry (2004) 161:1537–1547.
  • •The conclusions about efficacy and low rates of switching into mania presented in the manuscript are severely limited by the short duration of the acute trials reviewed.
  • SILVERSTONE T: Moclobemide versus imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr. Scand. (2001) 104:104–109.
  • NEMEROFF CB, EVANS DL, GYULAI L et al.: Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am. J. Psychiatry (2001) 158:906–912.
  • HIMMELHOCH JM, THASE ME, MALLINGER AG, HOUCK P: Tranylcypromine versus imipramine in anergic bipolar depression. Am. J. Psychiatry (1991) 148:910–916.
  • COHN JB, COLLINS G, ASHBROOK E, WERNICKE JF: A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int. Clin. Psychopharmacol (1989) 4:313–322.
  • BAUMHACKL U, BIZIERE K, FISCHBACH R et al.: Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study. Br. J. Psychiatry (1989) 6(Suppl.):78–83.
  • NIEUWSTRATEN CE, DOLOVICH LR: Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann. Pharmacother. (2001) 35:1608–1613.
  • VIETA E, MARTINEZ-ARAN A, GOIKOLEA JM et al.: A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilisers. J. Clin. Psychiatry (2002) 63:508–512.
  • •The SNRI venlafaxine has an increased switch risk compared with the SSRI paroxetine.
  • POST RM: Second-generation antidepressants are less likely to induce switches into hypomania and mania in patients with depression./ Bipolar Disord. (2005) In press.
  • CALABRESE JR, MACFADDEN W, MCCOY R, MINKWITZ M, WILSON E, MULLEN J: Double-blind, placebo-controlled study of quetiapine in bipolar depression. Abstracts of the 157th Annual Meeting of the American Psychiatric Association, May 1–6, 2004.
  • ••Dramatic antidepressant, anti-anxiety, andpro-sleep effects of quetiapine 300 and 600 mg versus placebo, even by week 1.
  • TOHEN M, VIETA E, CALABRESE J et al: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry (2003) 60:1079–1088.
  • SACHS GS: Mood stabilisers alone versus mood stabilisers plus antidepressant in bipolar depression. ACNP 42nd Annual Meeting; 'Depression as the Unmet Need in Bipolar Disorder: Findings from Recent Studies,' December 11th (2003), San Juan, Puerto Rico.
  • BAKER RW, ZARATE CM, JR., BROWN E, SCHUH L, TOHEN MF: A three-week comparison of olanzapine versus risperidone in the treatment of bipolar mania: improvement in manic and depressive symptoms and treatment adherence. Abstracts of the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA, USA (2003).
  • MCINTYRE RS, MANCINI DA, SRINIVASAN J et al: The antidepressant effects of risperidone and olanzapine in bipolar disorder. Can J. Clin. Pharmacol. (2004) 11:e218–e226.
  • KECK PE, JR.: New antiepileptics in thetreatment of bipolar disorder. Syllabus and Proceedings Summary of the 2001 American Psychiatric Association Meeting, New Orleans, USA May 5–10 (2001) Abstract 34E, 93.
  • SCHMIDT AW, LEBEL LA, HOWARD HR, JR., ZORN SH: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur. j Pharmacol. (2001) 425:197–201.
  • KECK PE, JR., MCELROY SL: Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin. Investig Drugs (2003) 12:655–662.
  • GOODNICK PJ, JERRY JM: Aripiprazole: profile on efficacy and safety. Expert Opin. Pharmacother. (2002) 3:1773–1781.
  • BAPTISTA T, ZARATE J, JOOBER R et al.: Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr. Drug Targets (2004) 5:279–299.
  • •Weight gain is a major problem in treatment of bipolar depression in general and with some antipsychotics more than others.
  • TAMMINGA CA: Similarities and differences among antipsychotics. j Clin. Psychiatry (2003) 64\(Suppl. 17):7–10.
  • MCINTYRE RS, KONARSKI JZ, YATHAM LN: Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum. Psychopharmacol. (2004) 19:369–386.
  • JOHNSON BA, AIT-DAOUD N, BOWDEN CL et al: Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet (2003) 361:1677–1685.
  • •Highly positive data in primary alcoholism.
  • MATHEW NT, SAPER JR, SILBERSTEIN SD et al: Migraine prophylaxis with divalproex. Arch. Neurol (1995) 52:281–286.
  • SILBERSTEIN SD: Topiramate in migraine prevention: evidence-based medicine from clinical trials. NeuroL Sci. (2004) 25\(Suppl. 3):5244–5245.
  • SUPPES T: Review of the use of topiramate for treatment of bipolar disorders. J. Clin. Psychopharmacol (2002) 22:599–609.
  • MCELROY SL, ARNOLD LM, SHAPIRA NA et al: Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am. J. Psychiatry (2003) 160:255–261.
  • BERLANT JL: Topiramate in posttraumatic stress disorder: preliminary clinical observations. J. Clin. Psychiatry (2001) 62\(Suppl. 17):60–63.
  • BERLANT J, VAN KAMMEN DP: Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J. Clin. Psychiatry (2002) 63:15–20.
  • KAMPMAN KM, PETTINATI H, LYNCH KG et al: A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. (2004) 75:233–240.
  • MCINTYRE RS, MANCINI DA, MCCANN S et al: Topiramate versus bupropion SR when added to mood stabiliser therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord. (2002) 4:207–213.
  • KECK PEJ, MCELROY SL, FRIEDMAN LM: Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes./ Clin. Psychopharmacol (1992) 12:36S–41S.
  • FORD N: The use of anticonvulsants in posttraumatic stress disorder: case study and overview. J. Trauma Stress (1996) 9:857–863.
  • CLARK RD, CANIVE JM, CALAIS LA, QUALLS CR, TUASON VB: Divalproex in posttraumatic stress disorder: an open-label clinical trial. J. Trauma Stress (1999) 12:395–401.
  • HERTZBERG MA, BUTTERFIELD MI, FELDMAN ME et al.: A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol. Psychiatry (1999) 45:1226–1229.
  • PANDE AC, CROCKATT JG, JANNEY CA, WERTH JL, TSAROUCHA G: Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. (2000) 2:249–255.
  • FRYE MA, KETTER TA, KIMBRELL TA et al.: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. PsychopharmacoL (2000) 20:607–614.
  • PANDE AC, POLLACK MH, CROCKATT J et al.: Placebo-controlled study of gabapentin treatment of panic disorder./ Clin. Psychopharmacol. (2000) 20:467–471.
  • POLLACK MH, MATTHEWS J, SCOTT EL: Gabapentin as a potential treatment for anxiety disorders [letter]. Am. J. Psychiatry (1998) 155:992–993.
  • PANDE AC, DAVIDSON JR, JEFFERSON JW et al.: Treatment of social phobia with gabapentin: a placebo-controlled study. J. Clin. PsychopharmacoL (1999) 19:341–348.
  • BSCHOR T, LEWITZKA U, SASSE J et al.: Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms. Pharmacopsychiatry (2003) 36\(Suppl. 3):5230–5234.
  • BAUER M, DOPFMER S: Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies./ Clin. PsychopharmacoL (1999) 19:427–434.
  • BHAGWAGAR Z, GOODWIN GM: The role of lithium in the treatment of bipolar depression. Clin. Neurosci. Res (2002) 2:222–227.
  • AHRENS B, MULLER-OERLINGHAUSEN B, SCHOU M et al.: Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J. Affect. Disord. (1995) 33:67–75.
  • MULLER-OERLINGHAUSEN B, BERGHOFER A, AHRENS B: The antisuicidal and mortality-reducing effect of lithium prophylaxis: consequences for guidelines in clinical psychiatry. Can. J. Psychiatry (2003) 48:433–439.
  • •Lithium has unique therapeutic assets in reducing suicide and the increased medical mortality associated with the affective disorders.
  • MANJI HK, QUIROZ JA, SPORN Jet al.: Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol. Psychiatry (2003) 53:707–742.
  • •Lithium and valproate have important effects on neurotrophic factors.
  • SENATOROV VV, REN M, KANAI H, WET H, CHUANG DM: Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease. MoL Psychiatry (2004) 9:371–385.
  • CHEN RW, CHUANG DM: Long term lithium treatment suppresses p53 and Box expression but increases Bc1-2 expression. A prominent role in neuroprotection against excitotoxicity. J. Biol. Chem. (1999) 274:6039–6042.
  • CHEN G, ZENG WZ, YUAN PX et al.:The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bc1-2 in the CNS. Neurochem. (1999) 72:879–882.
  • MOORE GJ, BEBCHUK JM, HASANAT K et al.: Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bc1-2's neurotrophic effects? Biol. Psychiatry (2000) 48:1–8.
  • •The in vitro effects of lithium may be clinically relevant.
  • SILVERSTONE PH, WU RH, O'DONNELL T et al.: Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. Int. Clin. PsychopharmacoL (2003) 18:73–79.
  • MOORE GJ, BEBCHUK JM, WILDS TB,CHEN G, MANJI HK: Lithium-induced increase in human brain grey matter. Lancet (2000) 356:1241–1242.
  • POST RM, LEVERICH GS, DENICOFF KD et al.: Alternative approaches to refractory depression in bipolar illness. Depress. Anxiety (1997) 5:175–189.
  • COPPEN A. CHAUDHRY S, SWADE C: Folic acid enhances lithium prophylaxis. J. Affective Disord. (1986) 10:9–13.
  • •Folate is a useful adjunct to lithium.
  • COPPEN A, BAILEY J: Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J. Affect. Disord. (2000) 60:121–130.
  • •Folate is an effective adjunct to an SSRI in unipolar depression.
  • FAVA M, BORUS JS, ALPERT JE et al.: Folate, vitamin B12, and homocysteine in major depressive disorder. Am. J. Psychiatry (1997) 154:426–428.
  • TIEMEIER H, VAN TUIJL HR, HOFMAN A et al.: Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am. J. Psychiatry (2002) 159:2099–2101.
  • OSHER Y, SELA BA, LEVINE J, BELMAKER RH: Elevated homocysteine levels in euthymic bipolar disorder patients showing functional deterioration. Bipolar Disord. (2004) 6:82–86.
  • DAVIDSON JR, ABRAHAM K, CONNOR KM, MCLEOD MN: Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol. Psychiatry (2003) 53:261–264.
  • GOLDBERG JF, BURDICK KE, ENDICK CJ: Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilisers for treatment-resistant bipolar depression. Am. J. Psychiatry (2004) 161:564–566.
  • •Positive data of this D2, D3 agonist replicated by Zarate et aL [84].
  • LATTANZI L, DELEOSSO L, CASSANO P et al.: Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord. (2002) 4:307–314.
  • ZARATE CA, JR., PAYNE JL, SINGH J et al.: Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol. Psychiatry (2004) 56:54–60.
  • OLVER JS, CRYAN JF, BURROWS GD, NORMAN TR: Pindolol augmentation of antidepressants: a review and rationale. Aust. NZ. J. Psychiatry (2000) 34:71–79.
  • BRILEY M: New hope in the treatment of painful symptoms in depression. Curr. Opin. Investig Drugs (2003) 4:42–45.
  • BERIGAN TR: Atomoxetine used adjunctively with selective serotonin reuptake inhibitors to treat depression. Prim. Care Companion J. Clin. Psychiatry (2004) 6:93–94.
  • SACHS GS, LAFER B, STOLL AL et ell.: A double-blind trial of bupropion versus desipramine for bipolar depression./ Clin. Psychiatry (1994) 55:391–393.
  • GUILLE C, SHRIVER A, DEMOPULOS C, SACHS G: Bupropion versus desipramine in the treatment of bipolar depression. Bipolar Disord. (1999) 1\(Suppl. 1):33.
  • HENDERSON TA, HARTMAN K: Aggression, mania, and hypomania induction associated with atomoxetine. Pediatrics (2004) 114:895–896.
  • FERNANDES PP, PETTY F: Modafinil forremitted bipolar depression with hypersomnia. Ann. Pharmacother. (2003) 37:1807–1809.
  • DEBATTISTA C, LEMBKE A, SOLVASON HB, GHEBREMICHAEL R, POIRIER J: A prospective trial of modafinil as an adjunctive treatment of major depression. J. Clin. Psychopharmacol (2004) 24:87–90.
  • NINAN PT, HASSMAN HA, GLASS SJ, MCMANUS FC: Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. J. Clin. Psychiatry (2004) 65:414–420.
  • JAVITT DC: Glycine modulators in schizophrenia. Curr. Opin. Investig. Drugs (2002) 3:1067–1072.
  • CARPENTER WT BUCHANAN RW, JAVITT DC et al.: Is glutamatergic therapy efficacious in schizophrenia? ACNP Abstracts (2004).
  • ZARATE CA Jr, PAYNE JL, QUIROZ Jet al.: An open-label trial of riluzole in patients with treatment-resistant major depression. Am. J. Psychiatry (2004) 161:171–174.
  • FERGUSON J, MCDONALD S, BELL J,XIE Y, MENDELS J: Evaluation of the antidepressant effect of memantine in patients with major depressive disorder. Abstracts of the 42nd Annual ACNP Meeting, December 7-11(2003) San Juan, Puerto Rico.
  • GRUNZE H, DITTMANN S, NOLEN W et al.: Acamprosate as adjunctive treatment in rapid cycling bipolar disorder: an open pilot study. Acta Psychiatr. Scand. (2004) 110:21.
  • STRYJER R, STROUS RD, SHAKED G et al.: Amantadine as augmentation therapy in the management of treatment-resistant depression. Int. Clin. Psychopharmacol. (2003) 18:93–96.
  • STANCER HC, PERSAD E: Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Clinical observations. Arch. Gen. Psychiatry (1982) 39:311–312.
  • BAUMGARTNER A, BAUER M, HELLWEG R: Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: An open clinical trial. Neuropsychopharmacol. (1994) 10:183–189.
  • BAUER M, HELLWEG R, GRAF KJ, BAUMGARTNER k Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacol (1998) 18:444–455.
  • BAUER M, PRIEBE S, BERGHOFER A et al.: Subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders. J. Affect. Disord. (2001) 64:35–42.
  • BAUER M, BERGHOFER A, BSCHOR T et al.: Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacol. (2002) 27:620–628.
  • ••A good summary of a perhaps underutilised approach to refractory bipolar depression.
  • LEIBENLUFT E, WEHR TA: Is sleep deprivation useful in the treatment of depression? Am. J. Psychiatry (1992) 149:159–168.
  • BENEDETTI F, BARBINI B, CAMPORI E et al.: Sleep phase advance and lithium to sustain the antidepressant effect of total sleep deprivation in bipolar depression: new findings supporting the internal coincidence model? J. Psychiatr. Res. (2001) 35:323–329.
  • POST RM, KOTIN J, GOODWIN FK: Effects of sleep deprivation on mood and central amine metabolism in depressed patients. Arch. Gen. Psychiatry (1976) 33:627–632.
  • EPPERSON CN, TERMAN M, TERMAN JS et al.: Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings. J. Clin. Psychiatry (2004) 65:421–425.
  • TERMAN M, TERMAN JS: Bright light therapy: side effects and benefits across the symptom spectrum. J. Clin. Psychiatry (1999) 60:799–808.
  • LEVITT AJ, JOFFE RT, KENNEDY SH: Bright light augmentation in antidepressant nonresponders. J. Clin. Psychiatry (1991) 52:336–337.
  • YAMADA N, MARTIN-IVERSON T, DAIMON K, TSUJIMOTO T, TAKAHASHI S: Clinical and chronobiolgical effects of light therapy on nonseasonal affective disorders. Biol Psychiatry (1995) 37:866–873.
  • BERSANI G, GARAVINI A: Melatonin add-on in manic patients with treatment resistant insomnia. Prog-. Neuropsychopharmacol. Biol. Psychiatry (2000) 24:185–191.
  • ROBERTSON JM, TANGUAY PE: Case study: the use of melatonin in a boy with refractory bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry (1997) 36:822–825.
  • AVERY DH, BOLTE MA, DAGER SR et al.: Dawn simulation treatment of winter depression: a controlled study. Am. J. Psychiatry (1993) 150:113–117.
  • TERMAN M, SCHLAGER D, FAIRHURST S, PERLMAN B: Dawn and dusk simulation as a therapeutic intervention. Biol. Psychiatry (1989) 25:966–970.
  • TERMAN M, TERMAN JS: Treatment of seasonal affective disorder with a high-output negative ionizer. J. Ahern. Complement. Med. (1995) 1:87–92.
  • ROHAN M, PAROW A, STOLL AL et ell.: Low-field magnetic stimulation in bipolar depression using an MRI-based stimulator. Am. J. Psychiatry (2004) 161:93–98.
  • PAULUS W: Transcranial direct current stimulation (tDCS). Clin. Neurophysiol (2003) 56(Suppl.):249–254.
  • ANDRADE C, KURINJI S: Continuation and maintenance ECT: a review of recent research. J ECT (2002) 18:149–158.
  • MCCALL WV REBOUSSIN DM, WEINER RD, SACKEIM HA: Titrated moderately suprathreshold versus fixed high-dose right unilateral electroconvulsive therapy: acute antidepressant and cognitive effects. Arch. Gen. Psychiatry (2000) 57:438–444.
  • SACKEIM HA, PRUDIC J, DEVANAND DP et al.: A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch. Gen. Psychiatry (2000) 57:425–434.
  • KOSEL M, FRICK C, LISANBY SH, FISCH HU, SCHLAEPFER TE: Magnetic seizure therapy improves mood in refractory major depression. Neuropsychopharmacol. (2003) 28:2045–2048.
  • LISANBY SH, LUBER B, SCHLAEPFER TE, SACKEIM HA: Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmaca (2003) 28:1852–1865.
  • POST RM, SPEER AM: rTMS and related somatic therapies: prospects for the future. In: TMS in Clinical Psychiatry. Belmaker RH, George MS (Eds.), American Psychiatric Association Press, Inc., Washington, DC, USA (2005) In press.
  • POST RM, KIMBRELL TA, MCCANN UD et al.: Repetitive transcranial magnetic stimulation as a neuropsychiatric tool: present status and future potential. ECT (1999) 15:39–59.
  • GRUNHAUS L, SCHREIBER S, DOLBERG OT, POLAK D, DANNON PN: A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol. Psychiatry (2003) 53:324–331.
  • •rTMS has promise, but needs further study.
  • PRIDMORE S, BRUNO R, TURNIER-SHEA Y, REID P, RYBAK M: Comparison of unlimited numbers of rapid transcranial magnetic stimulation (rTMS) and ECT treatment sessions in major depressive episode. Int. J. Neuropsychopharmacol (2000) 3:129–134.
  • DANNON PN, DOLBERG OT, SCHREIBER S, GRUNHAUS L: Three and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individuals-preliminary report. Biol. Psychiatry (2002) 51:687–690.
  • MCLOUGHLIN DM, MOGG A, ERANTI S, PLUCK G, BROWN R: Interim results of a pragmatic randomised controlled trial testing equivalence of ECT versus rTMS for major depressive disorder. Biol. Psychiatry (2004) 55\(Suppl. 1):1865.
  • RAMI-GONZALEZ L, BERNARDO M, BOGET T et al.: Subtypes of memory dysfunction associated with ECT: characteristics and neurobiological bases. J ECT (2001) 17:129–135.
  • MARANGELL LB, RUSH AJ, GEORGE MS et al.: Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry (2002) 51:280–287.
  • ••VNS is approved for refractory seizures andappears promising for unipolar and bipolar depression.
  • SACKEIM HA, RUSH AJ, GEORGE MS et al.: Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmaco/ogy (2001) 25:713–728.
  • COLOM F, VIETA E, MARTINEZ-ARAN A et al.: A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch. Gen. Psychiatry (2003) 60:402–407.
  • •An important area for enhancing therapeutic response.
  • COLOM F, VIETA E, REINARES M et al.: Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. J. Clin. Psychiatry (2003) 64:1101–1105.
  • CRAIGHEAD WE, MIKLOWITZ DJ: Psychosocial interventions for bipolar disorder. J. Clin. Psychiatry (2000) 61\(Suppl. 13):58–64.
  • MIKLOWITZ DJ, RICHARDS JA, GEORGE EL et al.: Integrated family and individual therapy for bipolar disorder: results of a treatment development study. Clin. Psychiatry (2003) 64:182–191.
  • VIETA E, COLOM F: Psychological interventions in bipolar disorder: From wishful thinking to an evidence-based approach. Acta Psychiatr. Scand. Suppl. (2004) 422:34–38.
  • MURRAY-SWANK AB, DIXON L: Family psychoeducation as an evidence-based practice. CNS Spear (2004) 9:905–912.
  • PERLICK DA, ROSENHECK RA, CLARKIN JF et al.: Impact of family burden and affective response on clinical outcome among patients with bipolar disorder. Psychiatr. Serv. (2004) 55:1029–1035.
  • NOWAK G, SIWEK M, DUDEK D et al.: Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol. J. Pharmacol (2003) 55:1143–1147.

Website

  • http://www.dbsalliance.org Depression and Bipolar Support Alliance.
  • http://www.bipolarnews.org BipolarNews.org.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.